Table 2 Summary of treatment and dose-limiting toxicities.

From: Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer

Days on Trial(days)

Cohort

Days on Treatment

Weeks Given AZD1775

Discontinued AZD1775

Weeks Given Cisplatin

Discontinued Cisplatin

Radiotherapy Completed

CTCAE Toxicity

DLT

Inability to Swallow

Group A

 100

1

10

1, 2

No

–

No

–

–

No

–

 99

1

10

1, 2

No

–

No

–

–

No

–

 98

1

10

1, 2

No

–

No

–

–

No

–

Group B

 384

1

20

1, 2

Yes

1 to 5

No

Yes

Dysphagia

Yes

Yes

 370

2

43

1, 2, 4

Yes

1 to 4

Yes

Yes

Febrile neutropenia

Yes^

No

 364

1

36

1, 2

Yes

1 to 3

No

Yes

Neutrophil count decreased

Mucositis

Yes

Yes

No

 363*

1

20

1, 2

Yes

1 to 5

No

Yes

-

No

–

 350

2

32

1, 2

Yes

1 to 5

No

Yes

Mucositis

Yes

Yes

  1. A summary of treatment received and dose limiting toxicities (DLTs) experienced by patients during the WISTERIA trial.
  2. *Patient chose to withdraw from the trial due to the burden of ongoing treatment
  3. ^This DLT was also reported as a serious adverse event (see Table 3).
  4. One patient in Group B withdrew from the trial before receiving AZD1775 so is not included in this table.
Back to article page